Bionime (TPE:4737) Ending Cash Position: NT$384 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4737 Bionime Corp TPE:4737
70 GF Score
Price NT$56.90
GF Value NT$54.00
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bionime Ending Cash Position?

Bionime TPE:4737 +0.71% 70 Ending Cash Position is NT$384 Mil as of Jun. 2026. GuruFocus rates TPE:4737 with a GF Score™ of 70/100 and a GF Value™ of NT$54.00 (Fairly Valued). The stock has 7 warning signs investors should review.

Bionime's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$384 Mil.

Bionime's quarterly Ending Cash Position declined from Dec. 2025 (NT$423 Mil) to Mar. 2026 (NT$387 Mil) and declined from Mar. 2026 (NT$387 Mil) to Jun. 2026 (NT$384 Mil).

Bionime's annual Ending Cash Position declined from Dec. 2023 (NT$392 Mil) to Dec. 2024 (NT$321 Mil) but then increased from Dec. 2024 (NT$321 Mil) to Dec. 2025 (NT$423 Mil).

Bionime Ending Cash Position Related Terms

Bionime Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Bionime's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionime Ending Cash Position Chart

Bionime Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 253.09 214.49 391.82 321.23 423.12

Bionime Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 317.87 307.28 423.12 387.48 383.71
TPE:4737
70GF Score
Bionime Corp TPE:4737
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionime Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Bionime's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=321.227+101.897
=423

Bionime's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=387.476+-3.768
=384

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$384 Mil mean?
Bionime (TPE:4737) has a Ending Cash Position of NT$384 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bionime and its competitors.
Is Bionime's Ending Cash Position too high?
Bionime's current Ending Cash Position is NT$384 Mil. Overall, Bionime has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's Ending Cash Position compare to ISRG and BDX?
Bionime's Ending Cash Position of NT$384 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bionime and its competitors. Bionime's current Ending Cash Position is NT$384 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$54.00, compared to a current price of NT$56.90 — trading 5.4% above its estimated fair value. The current Ending Cash Position is NT$384 Mil. Bionime's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Bionime (TPE:4737), the current Ending Cash Position is NT$384 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionime (TPE:4737) Overvalued in 2026?

Based on GuruFocus' analysis, Bionime stock appears to be overvalued. The current stock price of NT$56.90 is trading 5.4% above its estimated GF Value™ of NT$54.00. GuruFocus considers Bionime to be Fairly Valued.

Key valuation signals for TPE:4737:

  • Ending Cash Position: NT$384 Mil
  • GF Value™: NT$54.00 vs. price of NT$56.90 (5.4% above fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bionime Business Description

Address No. 100, Daqing Street, Section 2, South District, Taichung, TWN, 40242
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
70GF Score

Get the complete analysis for TPE:4737

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$56.90
Price
NT$54.00
GF Value